{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:47:12Z","timestamp":1790419632394,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>The impact of autoimmune cytopenias (AICs) on the chronic lymphocytic leukemia (CLL) clinical course and its prognostic significance remain a matter of controversial debate. This could be due to exclusion of patients with cytopenia from most clinical trials for this particular complication and the lack of standard diagnostic criteria and treatment approaches. We herein evaluate the prevalence and the prognostic significance of AICs among patients with CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is an observational retrospective study. Data on 101 patients with CLL were derived from the Oncology Center, Mansoura University, Egypt, database, which contains information on demographic and clinical characteristics at diagnosis and follow-up records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The prevalence of immune cytopenias was 11.9% among patients studied. Autoimmune hemolytic anemia was the most common autoimmune form in patients with cytopenia due to pure immune etiology (C immune group) with a prevalence of 6.9%. Patients with AICs and those in the C immune subgroup presented with more unfavorable parameters. Besides, patients with AICs showed lesser response to treatment and on restaging after initial treatment, significantly more patients without AICs moved to a more favorable stage. However, no parallel significant difference in the overall survival was found between patients without AICs and those with AICs or with immune and combined or infiltrative cytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We have shown a prevalence of 11.8% for AIC among our CLL patients. AIC was associated with unsatisfactory normalization of the hematological parameters even with therapy and lower number of patients with CLL downstaging in comparison with patients without AIC. These results suggest that AIC is a fingerprint of a biologically more aggressive disease even if no significant impact on overall survival was found.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T11:45:45Z","timestamp":1550922345000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia"],"prefix":"10.4103","volume":"12","author":[{"given":"Basma","family":"Atef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Azmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Aladle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Mabed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2019.01.004_b0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2019.01.004_b0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2010.036152","article-title":"Chronic lymphocytic leukemia and autoimmunity: a systematic review","volume":"96","author":"Hodgson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.01.004_b0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3109\/10428194.2013.834054","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?","volume":"55","author":"Visco","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2019.01.004_b0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2019.01.004_b0035","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0040","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance","volume":"116","author":"Moreno","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1468-0734.2000.00002.x","article-title":"Morphological and immunophenotypic features of chronic lymphocytic leukemia","volume":"4","author":"Matutes","year":"2000","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cyto.b.20135","article-title":"An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia","volume":"70","author":"Shankey","year":"2006","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.hemonc.2019.01.004_b0055","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0065","first-page":"828","article-title":"Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders","volume":"8","author":"Duek","year":"2006","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.hemonc.2019.01.004_b0070","first-page":"34","article-title":"Basic biology of autoimmune phenomena in chronic lymphocytic leukemia","volume":"25","author":"Pritsch","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminoncol.2006.01.011","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-012-1663-3","article-title":"Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases","volume":"92","author":"Shvidel","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0085","first-page":"730131","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"8","author":"D\u2019Arena","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0090","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.23861","article-title":"Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0095","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features","volume":"95","author":"Mauro","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0100","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3324\/haematol.2010.022079","article-title":"Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status","volume":"95","author":"Visco","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2019.01.004_b0105","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2007-07-101303","article-title":"The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia","volume":"111","author":"Dearden","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2019.01.004_b0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","article-title":"The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"141","author":"Zent","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2019.01.004_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10369","article-title":"Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"74","author":"Kyasa","year":"2003","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387619300056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201912020-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:23Z","timestamp":1787838563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201912020-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2019.01.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}